

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>In re United States Patent Application of:</b>		)	<b>Docket No.:</b>	<b>014811-673.119 US</b>
<b>Applicant(s):</b>	<b>Ekwuribe, et al.</b>	)	<b>Examiner:</b>	<b>Phyllis G. Spivack</b>
<b>Application No.:</b>	<b>10/594,046</b>	)	<b>Art Unit:</b>	<b>1614</b>
<b>Filing Date:</b>	<b>September 25, 2006</b>	)	<b>Confirmation No:</b>	<b>8968</b>
<b>Title:</b>	<b>METHODS AND COMPOSITIONS EMPLOYING 4-AMINOPHENYLACETIC ACID COMPOUNDS</b>	)	<b>Customer No.</b>	<b>24239</b>

**RESPONSE TO JUNE 21, 2011 OFFICE COMMUNICATION ISSUED IN U.S. PATENT APPLICATION NO. 10/594,046**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the June 21, 2011 Office Communication, applicants provide an interview summary of the telephonic conversation with Examiner Spivack wherein it was decided to and the term “and” after the clause “non-azo bonded 4-APAA compound;” so that claim 1 reads as follows:

1. A pharmaceutical composition comprising:  
a first therapeutic agent selected from the group consisting of:  
azo-bonded 4-aminophenylacetic acid (4-APAA) compound;  
non-azo bonded 4-APAA compound; and  
azo-bonded 5-aminosalicylic acid (5-ASA) compound;  
non-azo bonded 5-ASA compound; and  
a second therapeutic agent comprising a  
4-APAA compound azo bonded to a 5-ASA compound.